Limula unveils LimONE, a breakthrough in automated cell therapy manufacturing

Lausanne-based Limula has introduced LimONE, a fully automated cell therapy manufacturing platform designed to streamline production, reduce costs, and improve accessibility for patients. The company expects to deliver the first units by 2028.

Limula, a Vaud-based life sciences company, has taken a major step forward in the field of Cell and Gene Therapy (CGT) with the unveiling of LimONE, an end-to-end manufacturing solution designed to address the challenges of cost, scalability, and process standardization in the production of personalized cell therapies. Presented by Luc Henry, CEO of Limula, at Advanced Therapies Week in Dallas, the platform is set to transform how hospitals, biotech firms, and contract development and manufacturing organizations (CDMOs) handle cell therapy production.

LimONE consolidates multiple unit operations into a single closed consumable, minimizing labor-intensive steps, reducing infrastructure requirements, and ensuring process consistency. This innovation supports the production of multiple cell therapy types, including CAR-T and gene-edited hematopoietic stem cells. By using the same consumable throughout all development phases, Limula eliminates costly and time-consuming technology transfers, which often delay clinical trials.

The company’s approach combines Swiss precision engineering with deep CGT expertise. In partnership with Stockholm-based industrial design firm Fjaryl, Limula engaged over 20 academic and industry experts in a series of feedback workshops in Lausanne to refine LimONE’s design.

“Bringing together end-users from both academia and industry for these workshops was invaluable in shaping LimONE’s design,” explained Caroline Boudousquié, Head of Solutions at Limula. “This ensures LimONE is not just a technological innovation, but a practical, user-centered solution.”

Collaboration with industry leaders

Limula has established strong partnerships with key stakeholders across the CGT sector, including hospitals such as San Raffaele in Milan and Institut Paoli-Calmettes in Marseille, as well as process development specialists like Stemmatters in Portugal and biotech firms such as Achilles in England. These partners contribute resources and expertise to pilot studies, ensuring that LimONE meets rigorous performance standards before market launch.

With its focus on automation, accessibility, and scalability, LimONE represents a major advancement in the CGT industry. As the company engages with early adopters in the coming months, Limula aims to make life-saving cell therapies more widely available to patients worldwide.